Your browser doesn't support javascript.
Establishment of Murine Hybridoma Cells Producing Antibodies against Spike Protein of SARS-CoV-2.
Antipova, Nadezhda V; Larionova, Tatyana D; Siniavin, Andrei E; Nikiforova, Maria A; Gushchin, Vladimir A; Babichenko, Igor I; Volkov, Alexey V; Shakhparonov, Michail I; Pavlyukov, Marat S.
  • Antipova NV; Department of Functioning of Living Systems, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, 117997 Moscow, Russia.
  • Larionova TD; Institute of Medicine, Peoples' Friendship University of Russia (RUDN University), 17198 Moscow, Russia.
  • Siniavin AE; Faculty of Biology and Biotechnology, National Research University Higher School of Economics, 101000 Moscow, Russia.
  • Nikiforova MA; Department of Functioning of Living Systems, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, 117997 Moscow, Russia.
  • Gushchin VA; Department of Functioning of Living Systems, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, 117997 Moscow, Russia.
  • Babichenko II; N.F. Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, 123098 Moscow, Russia.
  • Volkov AV; N.F. Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, 123098 Moscow, Russia.
  • Shakhparonov MI; N.F. Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, 123098 Moscow, Russia.
  • Pavlyukov MS; Institute of Medicine, Peoples' Friendship University of Russia (RUDN University), 17198 Moscow, Russia.
Int J Mol Sci ; 21(23)2020 Dec 01.
Article in English | MEDLINE | ID: covidwho-954912
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
In 2020 the world faced the pandemic of COVID-19 severe acute respiratory syndrome caused by a new type of coronavirus named SARS-CoV-2. To stop the spread of the disease, it is crucial to create molecular tools allowing the investigation, diagnoses and treatment of COVID-19. One of such tools are monoclonal antibodies (mAbs). In this study we describe the development of hybridoma cells that can produce mouse mAbs against receptor binding domain of SARS-CoV-2 spike (S) protein. These mAbs are able to specifically detect native and denatured S proteins in all tested applications, including immunoblotting, enzyme-linked immunosorbent assay, immunofluorescence staining of cells and immunohistochemical staining of paraffin embedded patients' tissue samples. In addition, we showed that the obtained mAbs can efficiently block SARS-CoV-2 infection in in vitro experiments. Finally, we determined the amino acid sequence of light and heavy chains of the mAbs. This information will allow the use of corresponding peptides to establish genetically engineered therapeutic antibodies. To date multiple mAbs against SARS-CoV-2 proteins have been established, however, bigger sets of various antibodies will allow the detection and neutralization of SARS-CoV-2, even if the virus acquires novel mutations.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Spike Glycoprotein, Coronavirus / SARS-CoV-2 / Antibodies, Monoclonal / Antigens, Viral Limits: Animals / Humans Language: English Year: 2020 Document Type: Article Affiliation country: Ijms21239167

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Spike Glycoprotein, Coronavirus / SARS-CoV-2 / Antibodies, Monoclonal / Antigens, Viral Limits: Animals / Humans Language: English Year: 2020 Document Type: Article Affiliation country: Ijms21239167